Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Context-dependent antagonism between Akt inhibitors and topoisomerase poisons.

Gálvez-Peralta M, Flatten KS, Loegering DA, Peterson KL, Schneider PA, Erlichman C, Kaufmann SH.

Mol Pharmacol. 2014 May;85(5):723-34. doi: 10.1124/mol.113.088674.

2.

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.

Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H.

Mol Cancer Ther. 2010 Jul;9(7):1956-67. doi: 10.1158/1535-7163.MCT-09-1012.

3.

Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia.

Falà F, Blalock WL, Tazzari PL, Cappellini A, Chiarini F, Martinelli G, Tafuri A, McCubrey JA, Cocco L, Martelli AM.

Mol Pharmacol. 2008 Sep;74(3):884-95. doi: 10.1124/mol.108.047639.

4.

The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells.

Lin YH, Chen BY, Lai WT, Wu SF, Guh JH, Cheng AL, Hsu LC.

Naunyn Schmiedebergs Arch Pharmacol. 2015 Jan;388(1):19-31. doi: 10.1007/s00210-014-1032-y.

PMID:
25164962
5.

The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.

Liu R, Liu D, Trink E, Bojdani E, Ning G, Xing M.

J Clin Endocrinol Metab. 2011 Apr;96(4):E577-85. doi: 10.1210/jc.2010-2644.

6.

Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.

Chen KF, Chen HL, Tai WT, Feng WC, Hsu CH, Chen PJ, Cheng AL.

J Pharmacol Exp Ther. 2011 Apr;337(1):155-61. doi: 10.1124/jpet.110.175786.

7.

Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.

Ewald F, Grabinski N, Grottke A, Windhorst S, Nörz D, Carstensen L, Staufer K, Hofmann BT, Diehl F, David K, Schumacher U, Nashan B, Jücker M.

Int J Cancer. 2013 Nov;133(9):2065-76. doi: 10.1002/ijc.28214.

8.

PDK1 is a potential therapeutic target against angiosarcoma cells.

Wada M, Horinaka M, Yasuda S, Masuzawa M, Sakai T, Katoh N.

J Dermatol Sci. 2015 Apr;78(1):44-50. doi: 10.1016/j.jdermsci.2015.01.015.

PMID:
25726712
9.

The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy.

Simioni C, Martelli AM, Cani A, Cetin-Atalay R, McCubrey JA, Capitani S, Neri LM.

Oncotarget. 2013 Sep;4(9):1496-506.

10.

Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.

Cani A, Simioni C, Martelli AM, Zauli G, Tabellini G, Ultimo S, McCubrey JA, Capitani S, Neri LM.

Oncotarget. 2015 Mar 30;6(9):6597-610.

11.

MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines.

Almhanna K, Cubitt CL, Zhang S, Kazim S, Husain K, Sullivan D, Sebti S, Malafa M.

Cancer Biol Ther. 2013 Oct 1;14(10):932-6. doi: 10.4161/cbt.25939.

12.

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.

Bressanin D, Evangelisti C, Ricci F, Tabellini G, Chiarini F, Tazzari PL, Melchionda F, Buontempo F, Pagliaro P, Pession A, McCubrey JA, Martelli AM.

Oncotarget. 2012 Aug;3(8):811-23.

13.

Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways.

Kandil E, Tsumagari K, Ma J, Abd Elmageed ZY, Li X, Slakey D, Mondal D, Abdel-Mageed AB.

J Surg Res. 2013 Oct;184(2):898-906. doi: 10.1016/j.jss.2013.03.052.

PMID:
23602735
14.

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.

Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, Jücker M.

Mol Cancer. 2012 Nov 20;11:85. doi: 10.1186/1476-4598-11-85.

15.

Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer.

Wallin JJ, Guan J, Prior WW, Edgar KA, Kassees R, Sampath D, Belvin M, Friedman LS.

Sci Transl Med. 2010 Sep 8;2(48):48ra66. doi: 10.1126/scitranslmed.3000630.

16.

Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors.

Ewald F, Nörz D, Grottke A, Hofmann BT, Nashan B, Jücker M.

Invest New Drugs. 2014 Dec;32(6):1144-54. doi: 10.1007/s10637-014-0149-7.

PMID:
25152244
17.

The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.

Warshamana-Greene GS, Litz J, Buchdunger E, García-Echeverría C, Hofmann F, Krystal GW.

Clin Cancer Res. 2005 Feb 15;11(4):1563-71.

18.

Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo.

Zhao YY, Tian Y, Zhang J, Xu F, Yang YP, Huang Y, Zhao HY, Zhang JW, Xue C, Lam MH, Yan L, Hu ZH, Dinglin XX, Zhang L.

Drug Des Devel Ther. 2014 Oct 10;8:1827-37. doi: 10.2147/DDDT.S67961.

19.

Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.

Sajithlal GB, Hamed HA, Cruickshanks N, Booth L, Tavallai S, Syed J, Grant S, Poklepovic A, Dent P.

Mol Pharmacol. 2013 Oct;84(4):562-71. doi: 10.1124/mol.113.088005.

20.

AKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake.

Rashmi R, DeSelm C, Helms C, Bowcock A, Rogers BE, Rader JL, Grigsby PW, Schwarz JK.

PLoS One. 2014 Apr 4;9(4):e92948. doi: 10.1371/journal.pone.0092948. Erratum in: PLoS One. 2014;9(9):e107846. Rader, Janet [corrected to Rader, Janet L].

Items per page

Supplemental Content

Support Center